Melatonin effects on luteinizing hormone in postmenopausal women: a pilot clinical trial NCT00288262 by Kripke, Daniel F et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Women's Health
Open Access Research article
Melatonin effects on luteinizing hormone in postmenopausal 
women: a pilot clinical trial NCT00288262
Daniel F Kripke*1,2,3, Lawrence E Kline1,2, Farhad F Shadan1,2, 
Arthur Dawson1,2, J Steven Poceta1,2 and Jeffrey A Elliott3
Address: 1Scripps Clinic Sleep Center, 10666 North Torrey Pines Road, La Jolla, California 92037, USA, 2Department of Molecular and 
Experimental Medicine, The Scripps Research Institute, La Jolla, California 92037, USA and 3Department of Psychiatry, University of California, 
San Diego, La Jolla, California 92093-0667, USA
Email: Daniel F Kripke* - Kripke.Daniel@ScrippsHealth.org; Lawrence E Kline - LKline@ScrippsClinic.com; 
Farhad F Shadan - FFShadan@Yahoo.com; Arthur Dawson - ADawson1@san.rr.com; J Steven Poceta - JPoceta@Scripps.edu; 
Jeffrey A Elliott - JElliott@UCSD.edu
* Corresponding author    
Abstract
Background: In many mammals, the duration of the nocturnal melatonin elevation regulates seasonal
changes in reproductive hormones such as luteinizing hormone (LH). Melatonin's effects on human
reproductive endocrinology are uncertain. It is thought that the same hypothalamic pulse generator may
both trigger the pulsatile release of GnRH and LH and also cause hot flashes. Thus, if melatonin suppressed
this pulse generator in postmenopausal women, it might moderate hot flashes. This clinical trial tested the
hypothesis that melatonin could suppress LH and relieve hot flashes.
Methods: Twenty postmenopausal women troubled by hot flashes underwent one week of baseline
observation followed by 4 weeks of a randomized controlled trial of melatonin or matched placebo. The
three randomized treatments were melatonin 0.5 mg 2.5–3 hours before bedtime, melatonin 0.5 mg upon
morning awakening, or placebo capsules. Twelve of the women were admitted to the GCRC at baseline
and at the end of randomized treatment for 24-hour sampling of blood for LH. Morning urine samples
were collected twice weekly to measure LH excretion. Subjective responses measured throughout
baseline and treatment included sleep and hot flash logs, the CESD and QIDS depression self-ratings, and
the SAFTEE physical symptom inventory.
Results: Urinary LH tended to increase from baseline to the end of treatment. Contrasts among the 3
randomized groups were statistically marginal, but there was relative suppression combining the groups
given melatonin as contrasted to the placebo group (p < 0.01 one-tailed, Mann-Whitney U = 14.) Similar
but not significant results were seen in blood LH. There were no significant contrasts among groups in hot
flashes, sleep, depression, or side-effect measures and no significant adverse effects of any sort.
Conclusion:  The data are consistent with the hypothesis that melatonin suppresses LH in
postmenopausal women. An effect related to the duration of nocturnal melatonin elevation is suggested.
Effects of melatonin on reproductive endocrinology should be studied further in younger women and in
men. Larger studies of melatonin effects on postmenopausal symptoms would be worthwhile.
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Background
In vertebrates, melatonin serves as a hormonal signal of
night, and consequently, as a signal of the night's duration
through the changing seasons. In a number of mamma-
lian species, the duration of the nocturnal melatonin ele-
vation regulates seasonal changes in reproductive
hormones such as luteinizing hormone (LH), follicle-
stimulating hormone (FSH), and prolactin [1-4].
Whether melatonin regulates reproductive endocrinology
in humans has been uncertain. On the one hand, mela-
tonin was tested with some success as a contraceptive [5].
In a controlled trial, 3 mg. melatonin at bedtime evidently
suppressed LH in younger women as compared to pla-
cebo, but not among women of menopausal age [6]. Sev-
eral conditions of inadequate gonadal function or
amenorrhea may be associated with enhanced endog-
enous melatonin production, but not all reports have
been consistent [1,7-11]. A prolactin-stimulating effect
was noted in women given melatonin 2 mg at 16:00 and
20:00, but there was no significant effect on LH or TSH
[12]. Melatonin decreased LH in men in one study, [13]
and melatonin impaired sperm production in two young
men [14].
Wehr and colleagues subjected experimental subjects to 8
and 14 hours of complete darkness, without attempting to
regulate light levels when subjects were out of bed. Dra-
matic effects of long nights on melatonin, cortisol, and
prolactin were demonstrated [15]. The duration of mela-
tonin secretion was prolonged [16]. The duration of the
nocturnal prolactin elevation increased, but it was evident
from the mean plots that the peak values were higher dur-
ing short nights, and therefore, it is unclear what the effect
of long nights were on total daily prolactin secretion [17].
There were no significant changes in LH from baseline
constant routine measurement to measurement after 4
weeks of 14-hour nights; however, since only 3 blood
samples were obtained on each occasion, and LH is both
highly pulsatile and rather circadian, the sampling did not
conclusively address the possibility of effects on LH [17].
Moreover, a man and a woman subjected to 14-hour
nights for 15 weeks experienced a disturbing loss of pitui-
tary volume. In that one man, LH and FSH increased dur-
ing a period of normal nights that followed 15 weeks of
long nights, suggesting that secretion of these hormones
had been suppressed during the long nights [17].
On the other hand, some controlled trials of melatonin
have observed no suppressive effects on reproductive hor-
mones [18]. In a placebo-controlled crossover trial for one
month (spring) and 3 weeks (fall), 2 mg melatonin given
at 17:00 had no effect on LH [19]. Melatonin 1.5 mg
administered at 1600 for 8 days had no effect [20]. Mela-
tonin 10 mg administered at 10 PM had no effect on LH
or FSH over 28–40 days [21]. Morning acute administra-
tion of 3 mg melatonin was found to amplify LH pulses
and area under the curve almost 50% among women in
the early follicular phase [22].
In menopausal women, hot flashes are often synchronous
with pulsatile release of LH [23,24]. Although hot flashes
may not be directly caused by either GnRH or LH, the
same hypothalamic pulse generator may initiate both the
hot flash and the pulsatile endocrine release. Thus, if
melatonin suppressed this pulse generator in menopausal
women, it might moderate hot flashes. In our group, Suh-
ner et al. reasoned that by suppressing hot flashes, mela-
tonin might be an effective treatment for menopausal
sleep disturbances [25]. In four subjects, they found that
3 mg melatonin at bedtime significantly decreased noctur-
nal LH secretion after 2 weeks. However, there was no sig-
nificant reduction in hot flashes. Likewise, in another
study of melatonin effects on LH, there was no significant
reduction of hot flashes [6].
The current study was planned as an expanded test of the
hypothesis that melatonin could suppress LH and relieve
hot flashes by suppression of the hypothalamic pulse gen-
erator. Wishing to mimic the broader nocturnal mela-
tonin elevation occurring naturally in winter, we gave
melatonin not at bedtime but either 2.5–3.0 hours before
bedtime or at the time of awakening. We intended to com-
pare effects of evening and morning melatonin adminis-
tration, which might have opposite effects on circadian
timing. Lewy et al. had suggested that excessive melatonin
doses might be ineffective stimuli of the circadian system,
because blood levels might be elevated for too long [26].
Therefore, the relatively low oral dose of 0.5 mg was
selected, considering that even this dose may produce a
peak blood concentration well above the physiologic peak
[26].
Methods
Postmenopausal women troubled by hot flashes were
recruited for the research by newspaper advertising. Out
of 34 women interviewed for the study, 20 signed written
informed consent and completed the research. Almost all
of the others withdrew before or shortly after signing con-
sent, mostly because their symptoms were not suitable,
because they did not wish to adhere to the protocol, or
because inspection of arm veins suggested that establish-
ment of an intravenous sampling line might be difficult.
A steady dosage of hormone replacement therapy was not
considered an exclusion if it did not eliminate hot flashes.
The study adhered to the principles of the Helsinki Decla-
ration and was approved and supervised by the local Insti-
tutional Review Boards.BMC Women's Health 2006, 6:8 http://www.biomedcentral.com/1472-6874/6/8
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The protocol consisted of one baseline observation week
followed by 4 weeks of double-blind randomized treat-
ment with either melatonin 0.5 mg or placebo in identi-
cal-appearing capsules (Figure 1). Participants were
instructed to take one coded capsule 2.5–3.0 hours before
bedtime and one capsule in the morning upon awakening
every day for four weeks. Participants received 1) placebo
in the evening with 0.5 mg melatonin in the morning, 2)
melatonin 0.5 mg in the evening with placebo in the
morning, or 3) placebo both evening and morning. The
melatonin was Microtonin™ 500 µg manufactured by Car-
diovascular Research, Ltd., Concord, CA. The melatonin
content of the preparation was informally verified by
diluting capsules in water and assaying with the Bühl-
mann Melatonin Direct RIA. Random assignments were
generated by the Consulting Statistician for the Research
Pharmacist, who provided the medications in coded bot-
tles for evening and morning administration. Participants,
investigators, and General Clinical Research Center staff
were blind to treatment assignment.
During the baseline week and throughout the 4 weeks of
randomized treatment, participants completed a Daily
Log of Sleep and Hot Flashes. This consisted of daily nota-
tions of a) bedtime, b) wake-up time, c) the self-estimated
percentage of time-in-bed asleep, d) number of hot
flashes in 24 hours, and e) a 10 cm. visual analog estimate
of daily hot flash severity ranging from "mildest" to "most
severe." These self-observations were averaged on a
weekly basis. In addition, at the end of each of the 5
weeks, the participants completed two scales for self-rat-
ing depression for the previous week, the Center for Epi-
demiological Studies Depression Scale (CESD) and the
Quick Inventory of Depressive Symptomatology self-rat-
ing version (QIDS-SR), as well as the SAFTEE, a 96-item
symptom inventory designed to monitor adverse effects in
clinical trials [27].
At the end of the baseline week, participants were admit-
ted to the General Clinical Research Center for 25 hours,
so that venous blood could be sampled repeatedly. An
intravenous catheter in a forearm, with long extensions,
was established. So far as possible, 2.5 cc blood samples
were drawn every 20 min. for 24 hours for assays of lutei-
nizing hormone. Also at this first admission, the baseline
CESD, QIDS-SR, and SAFTEE scales were collected, the
participants were instructed in urine collection proce-
dures, and the randomized coded medications were pro-
vided for 4 weeks of treatment at home. During the
randomized treatment, participants collected a first morn-
ing urine specimen twice a week, measuring the volume,
recording the collection intervals, and freezing aliquots,
so that urinary LH excretion could be examined. On the
last day of the 4 weeks of randomized treatment, partici-
pants were readmitted to the General Clinical Research
Center for repeated 24-hour blood sampling and collec-
tion of all data forms. Participants who completed the
study were paid $440, or pro-rata for early discontinua-
tion.
The staff experienced considerable difficulty in maintain-
ing the venous catheters and obtaining blood specimens.
For the first 12 participants, of 1898 planned samples,
only 1090 samples were successfully frozen. However, at
least a few samples were obtained from each of the 12 par-
ticipants, making it possible to estimate daily mean LH
blood concentration. Because of the missed samples and
the small number of subjects completing the blood sam-
pling procedures, it was not possible to analyze the
parameters of pulsatile LH secretion.
We had originally planned to complete study of 30 sub-
jects to have reasonable power for the endocrine studies,
recognizing that for the sleep, hot flashes, and symptom
data, a much larger number of subjects would be desirable
for adequate power [28]. After 13 participants had com-
pleted the protocol (blood LH from one could not be
used), it was unfortunately necessary to discontinue the
inpatient studies, because of loss of GCRC funding. An
additional 7 subjects completed the protocol entirely at
home, collecting urine but no blood samples. Resources
did not permit recruitment of the final 10 subjects
planned.
Assays
LH levels in blood and urine were measured using DSL-
10-460 ActiveR LH Elisa kits (Diagnostic System Laborato-
The experimental protocol Figure 1
The experimental protocol. The protocol consisted of 1 
baseline week followed by 4 weeks of randomized treatment. 
GCRC admissions for blood sampling were scheduled at the 
end of baseline and at the end of treatment. Symptom forms 
were obtained weekly and morning urine samples twice 
weekly. Hot Flashes and Sleep logs were completed daily.
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ries, Inc, Webster, TX.) This is an enzymatically amplified
"one-step" sandwich-type immunoassay. The manufac-
turer states that there is no detectable cross-reactivity with
TSH, FSH, and hCG. Blood samples were measured by
direct addition of 50 µL serum, whereas urine samples
were measured by diluting 1:1 with zero standards (each
at 25 µL). For accuracy, above-scale LH urine samples (>
180 mIU/ml) were re-assayed at increased dilutions. The
sensitivity of the EIA is 0.1 mIU/ml. At mean LH concen-
trations of 3.2 mIU/ml and 30.8 mIU/ml, intra-assay coef-
ficients of variation were 2.2% and 4.9% respectively, and
inter-assay CVs were 2.9% and 4.8% respectively. Urinary
rates of LH excretion (mIU/hr) were computed by multi-
plying the urine LH concentration (mIU/ml) by the urine
excretion rate (ml/hr) calculated over the interval between
voidings. Measured urinary LH excretion was quite erratic
from day to day, with the daily standard deviation being
69% of the mean. Therefore, for each subject, daily urine
LH mIU/hr values outside a range of ± 2SD were ignored,
in most cases leaving 8–9 values for computation of
slopes. The first and last values meeting the ± 2SD criteria
were also selected to explore changes in urinary LH excre-
tion during treatment.
Statistics
Contrasts between groups were examined using ANOVA,
with the initial score as the covariate. When appropriate
due to the distributions, these results were confirmed with
nonparametric analyses, which in the case of LH meas-
ures, were applied to change scores.
Results
The 20 participants completing the study had a mean age
of 59 years (range 51–69).
Luteinizing hormone
As expected due to random group assignment, baseline
values of urinary LH excretion among the 3 groups were
not significantly different, but the group which would be
randomized to receive melatonin in the evening averaged
substantially higher excretion than the other two groups.
Therefore, the percent changes between first and last sam-
ples divided by the initial level of the first sample were
examined to determine effects of randomized treatments.
Contrasting urinary LH excretion among the 3 groups,
these change scores adjusted for the initial level were mar-
ginally different (Kruskal-Wallace p < 0.06, DF = 2); how-
ever, combining the two melatonin groups because of the
small N and the prospective prediction that melatonin at
both times would suppress LH, there was suppression
among those given melatonin as contrasted to the placebo
group (p < 0.01 one-tailed, Mann-Whitney U = 14.) Like-
wise, the slopes of the urine LH excretion (including up to
8 bi-weekly samples) were lower among those receiving
melatonin than placebo (p < 0.06, one-tailed, Mann-
Whitney U = 22). There were no significant differences
between morning and evening melatonin results. Urinary
luteinizing hormone results are shown in Figure 2.
In the smaller subgroups which provided blood LH sam-
ples, the averaged baseline concentrations were 55 mIU/
ml among those that would randomly be given melatonin
in the evening, 28 mIU/ml among those to receive morn-
ing melatonin, and 23 mIU/ml among those receiving
only placebo (Kruskal-Wallace p = 0.02, DF = 2). For
blood LH, change scores were not significantly different
among the 3 groups, or when contrasting the two mela-
tonin groups combined with the placebo group. On over-
all average, mean blood LH increased slightly (not
significantly) from the first to the last collection, with a
17% ± SD 27% increase in the placebo group, a 9% ± SD
19% increase in the evening melatonin group, and an
11% ± SD 24% decrease in the morning melatonin group.
For the observed differences between the morning and
evening melatonin groups and the placebo group in
blood LH change scores, 14 cases in each group would be
needed for 82% power to distinguish the groups, mode-
ling ANOVA. Using the observed urine data, 27 cases in
each group would be needed for 80% power. Blood LH
results are shown in Figure 3.
The rank-order correlation of average blood LH at base-
line versus the first urine excretion sample was rS = 0.84 (P
Urinary LH results Figure 2
Urinary LH results. Above, the means and 95% confidence 
intervals of urinary luteinizing hormone excretion are shown 
in units of mIU/hr. For the morning melatonin, evening mela-
tonin, and placebo groups, both the initial and final samples 
are illustrated, with a line representing the direction of 
change. Below, the change ratios from first to last sample are 
plotted as filled circles for each subject, ranging from a 90% 
decrease to a 13-fold increase.
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< 0.001). The final treatment measures were correlated rS
= 0.73 (P < 0.01). The adjusted changes in urine LH excre-
tion and blood LH concentration were positively but not
significantly correlated.
Hot flashes
Reported hot flashes per day averaged 8.9 in the baseline
week and 7.8 in the final week of randomized treatment.
There was no significant difference between groups in hot
flashes change, but the trend was for the placebo group to
report the most improvement (contrary to prediction).
Similarly, reported severity on the visual-analog scales
dropped from 47 at baseline to 37 in the final week, with
the greatest drop in the placebo group, though group con-
trasts were not significant. Likewise, changes were not sig-
nificant between groups in the product of the reported
number of hot flashes times the reported severity.
Changes in hot flashes from baseline to the end of treat-
ment were not significantly correlated with changes in
blood or urinary LH over the same interval.
Sleep
In the baseline week, the participants reported an average
bedtime of 10:52 PM and an average uptime of 06:41 AM,
with an average of 85% of the time-in-bed spent asleep.
Though reported sleep percent increased to 88% at the
end of treatment, there were no significant contrasts
between treatment groups. The prediction that evening
melatonin administration would phase-shift sleep times
earlier than would morning melatonin (based on the
melatonin phase-response curve) [29] was not confirmed.
Mood
On the CESD, mood improved from an average score of
7.5 at baseline to 6.9 in the final week. A CESD score >16,
which is a sensitive screening criterion for major depres-
sion, was reported by 4 women at baseline, but only by 2
at the end of treatment. Perhaps because the group which
would receive morning melatonin included the partici-
pant with the highest CESD (which improved during the
study), that group showed the greatest improvement, but
the contrasts between groups were not significant. Simi-
larly, the average QIDS scores improved from 5.2 to 4.3
from baseline to the end of randomized treatments, with
no significant differences between groups.
Adverse effects
There were no clinically significant or severe adverse
effects reported during randomized treatment with mela-
tonin or placebo. Some women felt that the medication
caused mild sleepiness, but it was tolerable. The SAFTEE
symptom inventory displayed a 9.2% average reduction of
diverse medical symptom reports from baseline to the end
of treatment. Seventeen classes of symptoms and 10 indi-
vidual items related to sleepiness and mood were exam-
ined, but there were no significant contrasts between
randomized groups.
Discussion
To summarize, this trial tended to confirm a preliminary
study of Suhner et al. [25] and support the hypothesis that
melatonin given to postmenopausal women can suppress
luteinizing hormone as compared to placebo. This result
was statistically marginal. The amount of suppression
compared to placebo was very modest, considering the
high levels of secretion among women of this age. Indeed,
since participants receiving placebo showed higher LH at
the end of treatment than at baseline, suppression in the
group receiving melatonin in the evening was suggested
merely by a smaller percentage increase than in the pla-
cebo group. The directions of change were similar in both
blood and urine LH. Urine results were far more erratic,
but perhaps because data for urine LH were available for
more subjects, the contrasts were somewhat more statisti-
cally significant. Because fewer subjects than planned
were studied and the statistical outcome was not conclu-
sive, these results certainly need replication.
It was interesting to observe that morning melatonin was
associated with more suppression of LH than evening
melatonin, though not significantly so. Perhaps mela-
tonin administration 4–5 hours before bedtime might
have served to make the evening onset of melatonin more
Blood LH results Figure 3
Blood LH results. Above, the means and 95% confidence 
intervals of blood luteinizing hormone are shown in mIU/ml. 
For the morning melatonin, evening melatonin, and placebo 
groups, both the initial and final samples are illustrated, with 
a line representing the direction of change. Below, the 
changes from first to last sample are plotted as filled circles 
for each subject, ranging from 54% decrease to a 49% 
increase. Note that although the dispersion of change scores 
was much smaller for blood than for urinary measures of LH, 
the small sample sizes for blood LH provided weaker power 
to contrast groups.
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dramatically early and more effective. The investigators
had not chosen to give evening melatonin 4–5 hours
before bedtime, because it was believed that evening seda-
tion and a possibly unwanted advance in sleep timing
might be more severe with earlier administration.
It would be important to examine melatonin effects on
the reproductive endocrinology of women of other ages
and effects on men. Due to the excess LH secretion of
postmenopausal women, effects of melatonin were not
expected to be harmful to this group. However, if mela-
tonin interferes with the reproductive endocrinology of
women attempting to have children or suppresses LH
(and thus testosterone) among men, such effects might be
quite unwelcome. Since melatonin is becoming popular
in the treatment of children with developmental prob-
lems, it would also be important to explore whether mela-
tonin interferes with their endocrine development.
The observations were consistent with the hypothesis that
photoperiodic mechanisms are active in human physiol-
ogy. The timing chosen (well before bedtime or after aris-
ing) and the low dosage of melatonin, designed to
simulate effects of a natural winter photoperiod upon the
melatonin profile, may explain why we were able to dem-
onstrate this marginal melatonin effect on LH, when other
studies have not had similar results. Both the before-bed-
time and morning administration would tend to extend
the duration of the nightly melatonin elevation. Possibly,
other studies have failed to document an effect of mela-
tonin on LH because bedtime dosing or use of higher
doses creates 24-hour melatonin profiles less similar to
those produced by a natural winter photoperiod.
Nevertheless, it might be possible to further optimize tim-
ing and dosage.
Conclusion
The results of this study did not support our hypothesis
that melatonin would improve sleep and suppress hot
flashes among symptomatic postmenopausal women, but
there were no significant adverse effects, and LH was pos-
sibly suppressed. There were too few subjects to provide
adequate power for exploration of symptomatic effects,
especially considering the well-known placebo responses
in studies of this type [28]. Therefore, larger studies of
melatonin effects on postmenopausal women with hot
flashes are needed.
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